Stage-gate process for life sciences and medical innovation investment

Luis R. Soenksen, Youseph Yazdi

Research output: Contribution to journalArticle

Abstract

Life science innovation has led to significant improvements in clinical outcomes and has been a source of financial growth for individuals and institutions capable of performing appropriate investments in this sector. Several groups have developed methodologies to assist medical technology innovators in the design and development activities. Unfortunately, these tools have not aided the general investment community to profit from these enterprises. This situation has contributed to a general reduction in risk capital directed towards life sciences compared to other industries. We review the current investment practices in the life science sector and present a comprehensive stage-gate model that aims to captures this investment process. An analysis of best practices and in-depth interviews with 68 life sciences investors and entrepreneurs worldwide are used to support such model. A single case-control study comparing life science investment execution within two similar investment firms was conducted to evaluate feasibility in the implementation of these practices. The stage-gate model includes (I) General vision and investment strategy definition; (II) Venture search, screening and rapid pre-evaluation; (III) Due diligence and negotiation of terms; (IV) Portfolio management, evaluation, and exit. The difference in execution of investment and results from a post-performance Root Cause Analysis were consistent with a reduction in perceived risk from the case company trained with the proposed model compared to the control. This suggests that our developed model and process may be useful in encouraging life sciences investment via evidence-based evaluations.

Original languageEnglish (US)
JournalTechnovation
DOIs
StateAccepted/In press - Aug 25 2016

Fingerprint

Innovation
Medical innovation
Life sciences
Industry
Profitability
Screening
Evaluation

Keywords

  • Innovation
  • Investment
  • Life science
  • Medical devices
  • Process
  • Stage-gate

ASJC Scopus subject areas

  • Engineering(all)
  • Management of Technology and Innovation

Cite this

Stage-gate process for life sciences and medical innovation investment. / Soenksen, Luis R.; Yazdi, Youseph.

In: Technovation, 25.08.2016.

Research output: Contribution to journalArticle

@article{374242da20424545b7dbff0533f0b9b7,
title = "Stage-gate process for life sciences and medical innovation investment",
abstract = "Life science innovation has led to significant improvements in clinical outcomes and has been a source of financial growth for individuals and institutions capable of performing appropriate investments in this sector. Several groups have developed methodologies to assist medical technology innovators in the design and development activities. Unfortunately, these tools have not aided the general investment community to profit from these enterprises. This situation has contributed to a general reduction in risk capital directed towards life sciences compared to other industries. We review the current investment practices in the life science sector and present a comprehensive stage-gate model that aims to captures this investment process. An analysis of best practices and in-depth interviews with 68 life sciences investors and entrepreneurs worldwide are used to support such model. A single case-control study comparing life science investment execution within two similar investment firms was conducted to evaluate feasibility in the implementation of these practices. The stage-gate model includes (I) General vision and investment strategy definition; (II) Venture search, screening and rapid pre-evaluation; (III) Due diligence and negotiation of terms; (IV) Portfolio management, evaluation, and exit. The difference in execution of investment and results from a post-performance Root Cause Analysis were consistent with a reduction in perceived risk from the case company trained with the proposed model compared to the control. This suggests that our developed model and process may be useful in encouraging life sciences investment via evidence-based evaluations.",
keywords = "Innovation, Investment, Life science, Medical devices, Process, Stage-gate",
author = "Soenksen, {Luis R.} and Youseph Yazdi",
year = "2016",
month = "8",
day = "25",
doi = "10.1016/j.technovation.2017.03.003",
language = "English (US)",
journal = "Technovation",
issn = "0166-4972",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Stage-gate process for life sciences and medical innovation investment

AU - Soenksen, Luis R.

AU - Yazdi, Youseph

PY - 2016/8/25

Y1 - 2016/8/25

N2 - Life science innovation has led to significant improvements in clinical outcomes and has been a source of financial growth for individuals and institutions capable of performing appropriate investments in this sector. Several groups have developed methodologies to assist medical technology innovators in the design and development activities. Unfortunately, these tools have not aided the general investment community to profit from these enterprises. This situation has contributed to a general reduction in risk capital directed towards life sciences compared to other industries. We review the current investment practices in the life science sector and present a comprehensive stage-gate model that aims to captures this investment process. An analysis of best practices and in-depth interviews with 68 life sciences investors and entrepreneurs worldwide are used to support such model. A single case-control study comparing life science investment execution within two similar investment firms was conducted to evaluate feasibility in the implementation of these practices. The stage-gate model includes (I) General vision and investment strategy definition; (II) Venture search, screening and rapid pre-evaluation; (III) Due diligence and negotiation of terms; (IV) Portfolio management, evaluation, and exit. The difference in execution of investment and results from a post-performance Root Cause Analysis were consistent with a reduction in perceived risk from the case company trained with the proposed model compared to the control. This suggests that our developed model and process may be useful in encouraging life sciences investment via evidence-based evaluations.

AB - Life science innovation has led to significant improvements in clinical outcomes and has been a source of financial growth for individuals and institutions capable of performing appropriate investments in this sector. Several groups have developed methodologies to assist medical technology innovators in the design and development activities. Unfortunately, these tools have not aided the general investment community to profit from these enterprises. This situation has contributed to a general reduction in risk capital directed towards life sciences compared to other industries. We review the current investment practices in the life science sector and present a comprehensive stage-gate model that aims to captures this investment process. An analysis of best practices and in-depth interviews with 68 life sciences investors and entrepreneurs worldwide are used to support such model. A single case-control study comparing life science investment execution within two similar investment firms was conducted to evaluate feasibility in the implementation of these practices. The stage-gate model includes (I) General vision and investment strategy definition; (II) Venture search, screening and rapid pre-evaluation; (III) Due diligence and negotiation of terms; (IV) Portfolio management, evaluation, and exit. The difference in execution of investment and results from a post-performance Root Cause Analysis were consistent with a reduction in perceived risk from the case company trained with the proposed model compared to the control. This suggests that our developed model and process may be useful in encouraging life sciences investment via evidence-based evaluations.

KW - Innovation

KW - Investment

KW - Life science

KW - Medical devices

KW - Process

KW - Stage-gate

UR - http://www.scopus.com/inward/record.url?scp=85017516587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017516587&partnerID=8YFLogxK

U2 - 10.1016/j.technovation.2017.03.003

DO - 10.1016/j.technovation.2017.03.003

M3 - Article

JO - Technovation

JF - Technovation

SN - 0166-4972

ER -